| 12th week of 2009 patent applcation highlights part 52 |
| Patent application number | Title | Published |
|---|
| 20090076008 | DEUTERIUM-ENRICHED FOSAPREPITANT - The present application describes deuterium-enriched fosaprepitant, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076009 | THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS - The invention concerns thiazole derivatives of Formula I | 2009-03-19 |
| 20090076010 | DEUTERIUM-ENRICHED LAMOTRIGINE - The present application describes deuterium-enriched lamotrigine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076011 | DEUTERIUM-ENRICHED TIRAPAZAMINE - The present application describes deuterium-enriched tirapazamine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076012 | Modulation of pathogenicity - The present invention relates to the use of compounds of the general Formula (I): | 2009-03-19 |
| 20090076013 | DEUTERIUM-ENRICHED SITAGLIPTIN - The present application describes deuterium-enriched sitagliptin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076014 | Methods of Administering Tetrahydrobiopterin, Associated Compositions, And Methods of Measuring - The present invention is directed to treatment methods of administering tetrahydrobiopterin, including in oral dosage forms, in intravenous formulations, and with food. Also disclosed herein are biopterin assays for measuring the amount of biopterin and metabolites of biopterin in a sample. | 2009-03-19 |
| 20090076015 | Tricyclic Spiro Compound Comprising Acyl Group Bound to Nitrogen Atom in the Ring - It is intended to provide an anticoagulant that has an extremely excellent FXa inhibitory action and an extremely weak hERG channel inhibitory action and can be orally administered, which is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof. | 2009-03-19 |
| 20090076016 | FORMULATIONS COMPRISING JORUMYCIN-, RENIERAMYCIN-, SAFRACIN- OR SAFRAMYCIN-RELATED COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES - Jorumycin, renieramycin, safracin and saframycin related compounds formulations, methods of preparing the same, articles of manufacture and kits with such formulations, and methods of treating proliferative diseases with the same formulations are provided. | 2009-03-19 |
| 20090076017 | DEUTERIUM-ENRICHED TRABECTEDIN - The present application describes deuterium-enriched trabectedin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076018 | DEUTERIUM-ENRICHED RANOLAZINE - The present application describes deuterium-enriched ranolazine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076019 | METHODS FOR TREATING NEUROLOGICAL DISORDERS OR DAMAGE - A clonogenic neurosphere assay is described that carries out high throughput screens (HTS) to identify potent and/or selective modulators of proliferation, differentiation and/or renewal of neural precursor cells, neural progenitor cells and/or self-renewing and multipotent neural stem cells (NSCs). Compositions comprising the identified modulators and methods of using the modulators and compositions, in particular to treat neurological disorders (e.g. brain or CNS cancer) or damage are also disclosed. | 2009-03-19 |
| 20090076020 | Cyclopropyl Amide Derivatives 978 - Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith. | 2009-03-19 |
| 20090076021 | THERAPEUTIC COMBINATIONS AND METHODS FOR CARDIOVASCULAR IMPROVEMENT AND TREATING CARDIOVASCULAR DISEASE - A therapeutic combination, useful in a co-therapy method for improving cardiovascular performance and/or treating cardiovascular diseases, is provided comprising a first agent and a second agent, wherein the first agent comprises a histone deacetylase inhibiting agent and the second agent comprises at least one nuclear hormone receptor ligand. | 2009-03-19 |
| 20090076022 | TARTRATE SALTS OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY - The present invention relates to tartrate salts of quinazoline containing zinc-binding moiety based derivatives that are inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The tartrate salts may further act as HDAC inhibitors. | 2009-03-19 |
| 20090076023 | Local Anesthetic Methods and Kits - Methods of reversing local anesthesia are disclosed. The methods comprise administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing anesthesia with a low dose of an alpha adrenergic receptor antagonist. Also disclosed are kits comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist. | 2009-03-19 |
| 20090076024 | Episomal Fusion Gene - The present invention relates to an episomal structure expressing a functional oncogene, whereby said oncogene is a fusion gene of two chromosomal gene fragments. More specifically, the invention relates to a NUP214-ABL1 fusion product, important in the development of T-cell acute lymphoblastic leukemia, to methods to detect the fusion and to methods to prevent the oncogenic activity of said fusion product. | 2009-03-19 |
| 20090076025 | DEUTERIUM-ENRICHED DASATINIB - The present application describes deuterium-enriched dasatinib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076026 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention provides compounds of formula I: | 2009-03-19 |
| 20090076027 | DEUTERIUM-ENRICHED LURASIDONE - The present application describes deuterium-enriched lurasidone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076028 | DEUTERIUM-ENRICHED ITRACONAZOLE - The present application describes deuterium-enriched itraconazole, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076029 | Compounds and Methods for Treating Obesity - Methods for selection of compounds for treatment of obesity, compounds selected by the disclosed methods, and methods of treatment of obesity, wherein a selective melanocortin-4 receptor compound is identified, which compound is further characterized in that it attenuates the binding of both an agonist, including alpha-melanocyte stimulating hormone, and an inverse agonist, including agouti-related protein, to a melanocortin receptor, including melanocortin-4 receptor. | 2009-03-19 |
| 20090076030 | Piperazine compounds - A compound selected from those of formula (I): | 2009-03-19 |
| 20090076031 | DEUTERIUM-ENRICHED BORTEZOMIB - The present application describes deuterium-enriched bortezomib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076032 | Derivatives of 18Beta-Glycyrrhetinic Acid - The present invention relates to novel derivatives of 18β-glycyrrhetinic acid and methods of synthesising the derivatives. Also included within the scope of the present invention are pharmaceutical compositions comprising the derivatives of the present invention and medical uses of the derivatives, including their use in inhibiting enzymes such as retinol dehydrogenases. The present invention also relates to methods of treating diseases, such as hyperproliferative diseases, neoplasms, cancers and photoageing. | 2009-03-19 |
| 20090076033 | Method for treating atherosclerosis employing an aP2 inhibitor and combination - A method is provided for treating atherosclerosis and related diseases, employing an aP2 inhibitor or a combination of an aP2 inhibitor and another antiatheroscletotic agent, for example, an HMG CoA reductase inhibitor such as pravastatin. | 2009-03-19 |
| 20090076034 | DEUTERIUM-ENRICHED BMS-690514 - The present application describes deuterium-enriched BMS-690514, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076035 | DEUTERIUM-ENRICHED PALIPERIDONE - The present application describes deuterium-enriched peliperidone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076036 | DEUTERIUM-ENRICHED RISPERIDONE - The present application describes deuterium-enriched risperidone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076037 | BICYCLIC PYRIMIDINE KINASE INHIBITORS - The present invention is directed to novel bicyclic pyrimidine compounds of Formula (I) or a form or composition thereof | 2009-03-19 |
| 20090076038 | DEUTERIUM-ENRICHED ENTECAVIR - The present application describes deuterium-enriched entecavir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076039 | DEUTERIUM-ENRICHED VALACYCLOVIR - The present application describes deuterium-enriched valacyclovir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076040 | DEUTERIUM-ENRICHED VALGANCICLOVIR - The present application describes deuterium-enriched valganciclovir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076041 | ACYCLIC NUCLEOSIDE DERIVATIVES - Methods and novel intermediates for the preparation of and the treatment with acyclic nucleoside derivatives of the formula: | 2009-03-19 |
| 20090076042 | DEUTERIUM-ENRICHED ERLOTINIB - The present application describes deuterium-enriched erlotinib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076043 | DEUTERIUM-ENRICHED ALFUZOSIN - The present application describes deuterium-enriched alfuzosin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076044 | VEGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY - The present invention relates to VEGFR inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The said derivatives may further act as HDAC inhibitors. | 2009-03-19 |
| 20090076045 | Non-nucleoside reverse transcriptase inhibitors - Compounds of formula I, wherein R | 2009-03-19 |
| 20090076046 | Compounds modulating c-fms and/or c-kit activity and uses therefor - Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof. | 2009-03-19 |
| 20090076047 | 2-Substituted Hydroxylaminopyrimidine, Method for the Production and the Use Thereof in the Form of Pesticides - 2-Substituted pyrimidines of the formula I, | 2009-03-19 |
| 20090076048 | DEUTERIUM-ENRICHED XALIPRODEN - The present application describes deuterium-enriched xaliproden, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076049 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 - The present invention relates to new compounds of formula (I), wherein R | 2009-03-19 |
| 20090076050 | SYNERGISTIC TUMOR-KILLING EFFECT OF RADIATION AND BERBERINE COMBINED TREATMENT IN LUNG CANCER - A method for treating a subject suffering cancer, comprising administering an effective amount of berberine or its acid or ester derivates to the subject in need of such treatment, and radiating the cancer of the subject. | 2009-03-19 |
| 20090076051 | DEUTERIUM-ENRICHED METHYLNALTREXONE - The present application describes deuterium-enriched methylnatrexone bromide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076052 | DEUTERIUM-ENRICHED NALMEFENE - The present application describes deuterium-enriched nalmefene, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076053 | METHODS AND COMPOSITIONS FOR TREATING PAIN - Methods and compositions are described for the modulation of central nervous system and/or fetal effects of substances. Methods and compositions are described for the modulation of efflux transporter activity to increase the efflux of drugs and other compounds out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide for the increase of efflux transporter activity at blood-brain, blood-CSF and placental-maternal barriers to increase the efflux of drugs and other compounds from physiological compartments, including central nervous system and fetal compartments. | 2009-03-19 |
| 20090076054 | TEST METHOD FOR ENDOTOXIN - An object of the present invention is to provide a method capable of detecting and quantifying endotoxin in a sample in which endotoxin derived from gram-negative bacteria cannot be accurately detected or quantified by the method described in Commentary of the Japanese Pharmacopoeia Fourteenth Edition, Hirokawa Publishing Co. 2001 B-63. It has been found that the above object can be achieved by performing an endotoxin test using a lysate reagent in which the lysate reagent is added into a sample in the presence of albumin and/or globulin. | 2009-03-19 |
| 20090076055 | DEUTERIUM-ENRICHED VINFLUNINE - The present application describes deuterium-enriched vinflunine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076056 | DEUTERIUM-ENRICHED TOPOTECAN - The present application describes deuterium-enriched topotecan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076057 | DEUTERIUM-ENRICHED DUTASTERIDE - The present application describes deuterium-enriched dutasteride, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076058 | DEUTERIUM-ENRICHED FINASTERIDE - The present application describes deuterium-enriched finasteride, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076059 | DEUTERIUM-ENRICHED DIANICLINE - The present application describes deuterium-enriched dianicline, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076060 | DEUTERIUM-ENRICHED TEMSIROLIMUS - The present application describes deuterium-enriched temsirolimus, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076061 | MUSCARINIC ACETYCHOLINE RECEPTOR ANTAGONISTS - Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided. | 2009-03-19 |
| 20090076062 | Organic Compounds - Disclosed are δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amide compounds of formula (I) | 2009-03-19 |
| 20090076063 | Carboxamide compound and use of the same - A carboxamide compound represented by the formula (I): | 2009-03-19 |
| 20090076064 | Compounds - Disclosed are compounds of Formula (I) wherein G, R | 2009-03-19 |
| 20090076065 | DEUTERIUM-ENRICHED MK-0812 - The present application describes deuterium-enriched MK-0812, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076066 | DEUTERIUM-ENRICHED ZOLPIDEM - The present application describes deuterium-enriched zolpidem, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076067 | PHARMACEUTICAL COMPOSITION COMPRISING AZARHODACYANINE COMPOUND AS ACTIVE INGREDIENT - The object of the invention is to provide pharmaceutical composition that can be used as a therapeutic and/or prophylactic agent. Particularly, the pharmaceutical composition of the invention has significant therapeutic effect and survival benefit for the disease caused by parasitic protozoa, and selective toxicity against the causative protozoa. The pharmaceutical composition comprises a compound represented by general formula (1). Particularly, the invention relates to a composition that is an effective therapeutic/prophylactic agent for malaria, | 2009-03-19 |
| 20090076068 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES - The present invention relates to imidazopyridin-2-one derivatives of the formula I with the definitions specified in the description, to their pharmaceutically usable salts and to their use as medicaments. | 2009-03-19 |
| 20090076069 | DEUTERIUM-ENRICHED APIXABAN - The present application describes deuterium-enriched apixaban, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076070 | HETERO COMPOUND - [Problems] To provide a useful compound as an active ingredient for a preventing and/or treating agent for rejection in the transplantation of an organ, bone marrow, or a tissue, an autoimmune disease, or the like, which has an excellent S1P | 2009-03-19 |
| 20090076071 | DEUTERIUM-ENRICHED RETAPAMULIN - The present application describes deuterium-enriched retapamulin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076072 | DEUTERIUM-ENRICHED TAFENOQUINE - The present application describes deuterium-enriched tafenoquine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076073 | THERAPEUTIC AMIDES - The invention provides compounds of the formula: | 2009-03-19 |
| 20090076074 | QUINOLINE DERIVATIVES - The invention concerns quinoline derivatives of Formula I | 2009-03-19 |
| 20090076075 | QUINOLINE DERIVATIVES - The invention concerns quinoline derivatives of Formula I | 2009-03-19 |
| 20090076076 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF - The present invention relates to semicarbazone or thiosemicarbazone inhibitors of cysteine proteases and methods of using such compounds to prevent and treat protozoan infections such as trypanosomiasis, malaria and leishmaniasis. The compounds also find use in inhibiting cysteine proteases associated with carcinogenesis, including cathepsins B and L. | 2009-03-19 |
| 20090076077 | Methods and Compositions for Selectin Inhibition - The present invention relates to the field of anti-inflammatory substances, and more particularly to novel compounds that act as antagonists of the mammalian adhesion proteins known as selecting. In some embodiments, methods for treating selectin mediated disorders are provided which include administration of compound of Formula I: | 2009-03-19 |
| 20090076078 | New compounds 966 - Compounds of Formula I, or pharmaceutically acceptable salts thereof: | 2009-03-19 |
| 20090076079 | DEUTERIUM-ENRICHED METHYLPHENIDATE - The present application describes deuterium-enriched methylphenidate, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076080 | DEUTERIUM-ENRICHED FEXOFENADINE - The present application describes deuterium-enriched fexofenadine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076081 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS - The invention relates to a compound of formula | 2009-03-19 |
| 20090076082 | DEUTERIUM-ENRICHED ALVIMOPAN - The present application describes deuterium-enriched alvimopan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076083 | DEUTERIUM-ENRICHED SAREDUTANT - The present application describes deuterium-enriched saredutant, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076084 | WOUND AND MUCOUS MEMBRANE DISINFECTANT - Aqueous wound and mucous membrane disinfectant containing a) octenidine dihydrochloride, and b) one or more active ingredients selected from the group ethanol, 1-propanol, 2-propanol, undecylene amidopropyl trimonium methosulfate, 3-(4-chlorophenoxy)-1,2-propanediol and/or sodium hydroxymethylglycinate and c) glycerin and/or 1,2-diols having 3 to 10 carbon atoms, and d) optionally surfactants, emulsifiers, solubilisers, pH regulators, dyestuffs, perfumes and/or thickeners, the agent being free of phenoxyethanol, phenoxypropanol, phenoxyisopropanol and organic acids. | 2009-03-19 |
| 20090076085 | DEUTERIUM-ENRICHED NICRAVEN - The present application describes deuterium-enriched nicraven, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076086 | SUBSTITUTED NICOTINAMIDE COMPOUNDS AND USES THEREOF - Substituted nicotinamide compounds corresponding to formula I | 2009-03-19 |
| 20090076087 | DEUTERIUM-ENRICHED ETORICOXIB - The present application describes deuterium-enriched etoricoxib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076088 | Thrombin Receptor Antagonists - A series of compounds represented by the structural formulas | 2009-03-19 |
| 20090076089 | DEUTERIUM-ENRICHED PANTOPRAZOLE - The present application describes deuterium-enriched pantoprazole, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076090 | Treated Expanded Polystyrene Foam - Expanded polystyrene coated with at least one organic pesticide, methods for making expanded polystyrene coated with at least one organic pesticide, and molded articles made from expanded polystyrene coated with at least one organic pesticide is provided herein. | 2009-03-19 |
| 20090076091 | INDAZOLE-HETEROARYL DERIVATIVES - The invention relates to novel indazole derivatives as cited in claim | 2009-03-19 |
| 20090076092 | METHOD FOR DISRUPTING REPRODUCTIVE PERFORMANCE OF ARTHROPODS - Disclosed is a method for disrupting reproductive performance of an adult arthropod pest comprising contacting the adult arthropod pest or its environment with a sub-lethal, reproduction-disruptive amount of a carboxamide arthropodicide, its N-oxide, or a salt thereof. | 2009-03-19 |
| 20090076093 | DEUTERIUM-ENRICHED ROSIGLITAZONE - The present application describes deuterium-enriched rosiglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076094 | NOVEL ANTIBACTERIAL COMPOUNDS - This invention relates to a novel purified compound PM181104, of formula: | 2009-03-19 |
| 20090076095 | DEUTERIUM-ENRICHED NICORANDIL - The present application describes deuterium-enriched nicorandil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076096 | 2-Pyridinylcycloalkylbenzamide derivatives and their use as fungicides - A compound of general formula (I): | 2009-03-19 |
| 20090076097 | DEUTERIUM-ENRICHED ATAZANAVIR - The present application describes deuterium-enriched atazanavir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076098 | METHODS, KITS, AND COMPOUNDS FOR DETERMINING RESPONSIVENESS TO TREATMENT OF A PATHOLOGICAL DISORDER BY EPOTHILONES - The invention provides methods, kits and compounds for determining the potential responsiveness of a subject suffering from a pathological disorder, including non-small cell lung cancer (NSCLC), to treatment with an epothilone by analyzing the gene expression profile and/or certain molecular markers in a sample obtained from said subject. The invention further relates to methods, compounds and uses of said compounds for treating subjects suffering from said pathologic disorder, optionally in combination with other therapeutic agents. Also provided are genes and/or proteins encoded by them whose expression level have been determined to differ between epothilone responders and epothilone non-responders. | 2009-03-19 |
| 20090076099 | DEUTERIUM-ENRICHED IXABEPILONE - The present application describes deuterium-enriched ixabepilone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076100 | DEUTERIUM-ENRICHED GSK625433 - The present application describes deuterium-enriched GSK625433, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076101 | Thiophene and Thiazole Substituted Trifluoroethanone Derivatives as Histone Deacetylase (HDAC) Inhibitors - The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts and tautomers thereof. Compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. They are also useful for treating neurodegenerative diseases, mental retardation, 10 schizophrenia, inflammatory diseases, restenosis, immune disorders, diabetes, cardiovascular disorders and asthma. | 2009-03-19 |
| 20090076102 | DEUTERIUM-ENRICHED MURAGLITAZAR - The present application describes deuterium-enriched muraglitazar, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076103 | STEM CELL DIFFERENTIATING AGENTS AND USES THEREFOR - The present invention relates to screens for compounds that can induce stem cell differentiation. In addition, isoxazoles and sulfonyl hydrazones are identified as general classes of compounds that can induce differentiation of stem cells into cells of neuronal and cardiac fate, respectively. | 2009-03-19 |
| 20090076104 | DEUTERIUM-ENRICHED LOSARTAN - The present application describes deuterium-enriched losartan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
| 20090076105 | PREVENTIVE OR THERAPEUTIC AGENT FOR CEREBRAL ISCHEMIC INJURY OR CEREBRAL ISCHEMIA REPERFUSION IN STROKE - The present invention provides a preventive or therapeutic agent for cerebral ischemic injury or cerebral ischemic reperfusion injury in stroke such as cerebral infarction and cerebral hemorrhage which exerts its effect through a different mechanism from that of conventional therapeutic agents and can be taken for along period. The present invention is a preventive or therapeutic agent for cerebral ischemic injury or cerebral ischemic reperfusion injury in stroke which contains 6-fluoro-2′,5′-dioxospiro[chroman-4,4′-imidazolidine]-2-carboxamide as an active ingredient. A particularly preferable compound is an optically resolved (2S,4S)-form of fidarestat. | 2009-03-19 |
| 20090076106 | 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels - This invention relates to novel 2-(phenylamino)benzimidazole derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). | 2009-03-19 |
| 20090076107 | DEUTERIUM-ENRICHED ODANSETRON - The present application describes deuterium-enriched ondansetron, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-19 |
